ATRX and neuroblastoma: However, inactivating ATRX mutations have also been identified in neuroblastoma, pancreatic neuroendocrine tumor, and multiple sarcomas, where they arise in distinct molecular and cellular contexts, indicating that oncogenic mechanisms of broad physiological relevance are likely mobilized by ATRX deficiency6.